![](https://tracker.live.rns-distribution.com/track.live-rns/4711073_75d1671758db0ed18eba2dbba83793b2.png)
OptiBiotix Health plc
("OptiBiotix" or the "Company")
21 March 2023
Change of Broker
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease, diabetes and skincare, announces that the Company gave three months' notice to its joint broker Cenkos Securities plc on 28 December 2022. As of 28 March 2023, that notice will be served and Cenkos will cease to be the Company's joint broker.
Peterhouse Capital will remain as the Company's sole broker.
The Directors of the Company are responsible for the release of this announcement.
For further information, please contact:
OptiBiotix Health plc | ||
Neil Davidson, Chairman | Contact via Walbrook below | |
Stephen O'Hara, Chief Executive | | |
|
| |
Cairn Financial Advisers LLP (NOMAD) | Tel: 020 7213 0880 | |
Liam Murray / Jo Turner / Ludovico Lazzaretti | | |
| | |
Peterhouse Capital Limited (Broker) | Tel: 020 7220 9797 | |
Duncan Vasey / Lucy Williams
| | |
Walbrook PR Ltd | Mob: 07876 741 001 | |
Anna Dunphy | | |
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness.
OptiBiotix has an extensive R&D programme working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.